#ASCO21: Gilead's Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients
With AstraZeneca and Daiichi sniffing at its trail, Gilead has worked hard to hold an advantage for ADC Trodelvy in particularly hard-to-treat breast cancer patients. Now, the drugmaker is reading out more late-stage data showing some benefit in earlier-line patients, and it could help carve a path forward to a bigger market share.
Gilead’s Trodelvy extended survival in a subgroup analysis of relapsed or refractory triple-negative breast cancer patients in the second line, a positive sign Gilead hopes could spell earlier lines of therapy for its TROP2-directed ADC, according to data from the Phase III ASCENT study set to be presented at this weekend’s #ASCO21.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.